» » . - |


.. , , , , E-mail: korzunai@mail.ru

( : - , ) - .

- :PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) MedLine (http://www.medscape.com/). : "trial" "stroke" "Meta-analysis" . 񳺿 1960 2003 . .

˲Ͳ Բֲ

:

AITIA, 1978, 319 -, 30% (Stroke 8 301 - 318 1978; Stroke 9 309 - 318 1978),

CCS, 1978, 863 -, 31% (N Engl JMed 299 53 - 59 1978),

AICLA, 1983, 808 -, 29% (Stroke 14 5 - 14 1983; Presse Med 12 3049 - 57 1983),

SPAF I, 1991 , 1200 -, 40% (N Engl J Med 1990; 322:863-8; Circulation 1991; 84:527-39),

SALT, 1991 , 1360 -, 18% (Lancet 1991; 338:1345-9),

UK-TIA, 1991 , 2435 -, 18% (J Neurol Neurosurg Psychiatry 1991; 54:1044-54; Gut 1995; 37:509-11),

ACAS, 1995 , 1662 -, 53% (Stroke 1989; 20:844-9; JAMA 1995; 273:1421-8),

ESPS1 1998 , 1306 -, 33% (J Neurol Sci 1998; 154:200-4),

ACE, 1999 , 2849 -, (Lancet 1999; 353:2179-84),

ESPS2 1999 , 6602 -, (Acta Neurol Scand1999; 99:54-60; Neurology 1999; 53:825-9),

:

CAPRIE, 1996 , 19 185 -, 87% (Lancet1996; 348:1329-39; Drug Safety 1999; 4:325-35),

˲Ͳ Բֲ

:

EAFT, 1993 , 1007 -, (Lancet 1993; 342:1255-62; NEngl J Med 1995; 333:5-10),

PATAF, 1998 , 729 -, (J Am Coll Cardiol 1998; 31 Suppl A: 344A),

SPINAF, 1992, 571 -, - 79% (p <0,002) (N Engl J Med 1992;327:1406-12),

SPIRIT, 1997 , 1243 -, ( 30 - 44) (Stroke 1997; 28:231),

TPT, 1997 , 5085 -, (Am J Cardiol 1990; 65 Suppl C: 7C-11C; J Neurol Neurosurg Psychiatry1997; 62:269-72; Lancet 1998; 351:233-41),

WARSS, 1997 , 1920 -, (Cerebrovasc Dis 1997; 7:100-12),

BAATAF, 1990 420 -, - 82% (p <0,002) (N Engl J Med 1990;323:1505-11; Am Heart J 1992;124:1567-73; Stroke 1993;24:1360-5),

AFASAK - 58% (p <0,03) (Lancet 1989;1:175-9; J Cardiovasc Electrophysiol 1998;9 Suppl:S86-96),

CAFA, 1991 , 378 -, - 16%, -9%, - 42% (p> 02) (J AmColl Cardiol 1991; 18:349-55; Can Med Assoc J 1996; 154:1669-74),

SPAF, 1990 , - 67% (N Engl J Med 1990; 322:863-8; Circulation 1991; 84:527-39),

( ) - 20 - 30.

̲ ˲Ͳ Բֲ

:

IST, 1997 , 19 435 -, (Lancet1997; 349:1569-81),

:

TOAST, 1998 1281 -, (JAMA1998; 279:1265-72),

˲Ͳ Բֲ

:

ASK, 1996 , 340 -, (JAMA1996; 267:961-6; Stroke 1996; 27:1524-9),

MAST-E, 1994, 300 -, (Clin TrialsMeta-Analysis 1993; 28:329-44; Lancet 1994; 345:57; N Engl J Med 1996; 335:145-50),

MAST-I, 1995 622 -, (Lancet1995; 346:1509-14; Lancet 1995; 346:1515),

:

ECASS, 1995 , 620 -, , (JAMA 1995; 274:1017-25; JAMA 1995; 274:1058-9),

ECASS II, 1998 , 800 -, 7 , , (Lancet1998; 352:1245-51),

ղò ˲Ͳ Բֲ

в:

NASCET, 1991 , 1212 -, 㳿 (Stroke 1991; 22:711-20; N Engl J Med1991; 325:445-53; J Neurosurg 1995; 83:778-82),

˲Ͳ Բֲ

:

SSSS, 1995 , 4444 -, 28%, 30% (Am J Cardiol 1993; 71:393-400; Lancet 1994; 344:1383-9; Am J Cardiol 1995; 76: 64C-8C;Lancet 1995; 345:1274-5; Arch Intern Med 1996; 156:2085-92; PharmacoEconomics1996; 9:101-5; Eur Heart J 1996; 17:1001-7),

HPS, 2001 , 20 536 -, 24% (Eur Heart J1999; 20:725-41; Ann Med Interne (Paris) 2001 Apr; 152 (3) :188-93; Am JCardiol2002 Mar 7; 89 (5A): 50C-57C; Int J Clin Pract. 2002 Jan-Feb; 56 (1) :53-6),.

:

CARE, 1999 , 4159 -, (Am J Cardiol 1991; 68:1436-46; NEngl J Med 1996; 335:1001-9; Circulation 1999; 99:216-23),

- :

- Circulation. 1995 Nov 1; 92 (9) :2419-25: 1981 -, 62% ,

- JAMA 1997 Jul 23-30; 278 (4) :313-21: 29 000 -, 29% (~ 1/3 -),

- Arch Intern Med. 1999 Aug 9-23; 159 (15) :1793-802: 21 303 -, - 23%, - 31%,.

- J Gen Intern Med. 1999 Dec; 14 (12) :763-74: 19 921 -, - 30% ( = 00005), - 36% ( = 000001),

- Cerebrovasc Dis. 2000 Mar-Apr; 10 (2) :85-92: 80 000 -, 23% -, ,

- Orv Hetil. 2000 Jul 2; 141 (27) :1501-5: 450 000 -, - 10 - 31%,.

- Ann Med Interne (Paris) 2001 Apr; 152 (3) :188-93: 32 000 -, 25% 15% , ( 29%, = 0049), ( 21%, = 00038)

- Circulation 2001 Jan 23; 103 (3) :387-92: 19 768 -, 22% (7% 35%, = 001), 25% (10% 38%) 23% (6% 37%),

- Arch Intern Med. 2003; 163:669-76: 83 161 -, ( 26%) ,

- BMJ. 2003 Jun 28; 326 (7404): 1423: 10 / 10%, 18 / - 17%,.

- Pharmacotherapy. 2003 Jun; 23 (6) :726-30: 57%,.

- BMJ. 2003 Jun 28; 326 (7404): 1419: (40 / 10 /), ' ( ,- ), , 08 /볺 75 / - - 80%,.

ò ˲Ͳ Բֲ

:

HOPE, 2000, 9541 -, 22%, 32%, 62% (Can J Cardiol 1996; 12:127-37; N Engl J Med2000; 342:145-53; N Engl J Med 2000; 342:154-60),

SECURE, 1999 , 732 -, ( ) (Am J Cardiol 1996; 78:914-9; Circulation1999; 100 Suppl I: I-185),.

:

PROGRESS, 2001, 6105 -, 28%,. , (J Hypertens1995; 13:1869-73; Lancet 2001; 358:1033-41),

Ͳ в 1 ò II Բֲ

:

-LIFE, 2003., 9193 -, 2. 5% (Circulation. 2003 Aug12; 108 (6) :684-90 Clin Ther. 2003 Apr; 25 (4) :1186-99 Curr Neurol Neurosci Rep.2003 Jan; 3 (1) :46-51),

:

-SCOPE, 2003 ., 4964 -, 2. 8%(J Hypertens. 2003 May; 21 (5) :875-86),.

:

PASS (n = 927): ( ) - (Stroke 1997; 28: 2347-52; CNSDrugs 1998; 9 Suppl 1: 41-9).

ֳ - ²Ͳ ϲ Ͳ.

, :

.

˳
N Engl J Med 315 1241 1986. Neurology 43S64 1993. N. Engl. J. Med. 327: 1253 1992. FDA 蠠
- / J Am Geriatr Soc 35 219 1987;
J Am Geriatr Soc 32 584 1984.
ͳ (̲) Cur Ther Res 48 597 1990.
2-- ( ):, , , , Neurology 43 301 1993;
Arch Gerontol Geriatr 16 149 1993;
Stroke 1997; 28: 2347-52;
CNS Drugs 1998; 9 Suppl 1: 41-9.
PASS (n = 927): ( ) -
- () Ann Neurol 18 705 1985. N Engl J Med, 308: 619 1983. FDA
ij (, ) Stroke 19 716 1988. , 򠠠 FDA 㳿
Gingko biloba Munch Med Wochenschr 133 S23 1991. 8  ,
1
() Jpn Pharmacol Ther 20 4 1992. * FDA, 堠 ( ), 
(, ,) Neuropsycho-biology 1992; 26 (1-2): 65-70. Pharmaco-psychiatry 1986 Sep; 19 (5): 378-85 2222 22 506.Pharma-therapeutica 1980; 2 (5): 317-22 2222 22 538.
- () Am J Psychiatry 150 321 1993. *
- (,) .., , , 1992. In Medline - *
(, ) Cochrane Database Syst Rev 2000; (2): CD000480
Int Clin Psychopharmacol 1991 Spring; 6 (1): 31-43.
FDA, 砠 (http://www.lenta.ru)
( ) .., , , 1992. In Medline - *
() .., , , 1992. In Medline - *
( ,) Ann NY Acad Sci 1994 Jun 30; 717: 253-69 2222 22 506.J Int Med Res 1991 Jul-Aug; 19 (4) :330-41 *
(, ) .., - 12 1993. In Medline - * , 蠠
() Z Hautkr 1987 Feb 15; 62 (4) :325-9 *
.., , , 1992. In Medline - , ⳿

* ϳ 䳿 .

:

:ϲ, ղò ˲ ( ), , , , (, ).

.



...


1 (0,00361)